Loading
Anavex Life Sciences Corp. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Donhauser Peter D.O., was filed 17 Jun 2024.
Anavex Life Sciences Corp.: what insiders have been doing
This page follows insider dealings at Anavex Life Sciences Corp. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. Anavex Life Sciences Corp. has had no insider filing for more than a year; the last one goes back to 12 September 2025.
Our records for Anavex Life Sciences Corp. go back to 2021, with 3 purchases and no sales on the open market in total.
In the same sector, recent insider purchases at Anixa Biosciences Inc and Vivos Inc also feature in our signals. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
12
Thresholds
n/a
Buy Volume
€39,354
3 ops. · all time
Sell Volume
n/a
n/a
Since the insiders bought
- -15.2%Entry US$11.34 · Close at T+365 US$9.62
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended September 2025 · cache
US$3.27
Analyst consensus
1 analystsUS$20.00Target US$20.00(+512%)US$20.00
Income statement
EBITDA-US$46.4M
Net income-US$46.4M0.0% margin
Valuation
PER (forward)-5.9x
P/Book2.5x
Beta1.14
Balance sheet & cash
Market capUS$303.1M
Free Cash Flow-US$39M
Profitability & ownership
ROE-30.8%
ROA-19.5%
% insiders1.7%
% institutions43.3%
Last declaration on 12 September 2025
Declarations12 total
187,500 shares@ US$5.04100.0% of flowCommon StockSEC:0001731122-25-001246:0
50,000 shares@ US$1.76100.0% of flowCommon stockSEC:0001731122-25-000837:0
500,000 shares@ US$0.9244.0% of flowCommon StockSEC:0001731122-25-000452:0
2,835 shares@ US$3.6451.7% of flowCommon StockSEC:0001731122-24-000957:0
Canonical exit: 12 Sept 2024 (T+90)
5,000 shares@ US$4.52100.0% of flowCommon StockSEC:0001731122-24-000828:0
Canonical exit: 13 Aug 2024 (T+90)
73,380 shares@ US$1.329.3% of flowCommon StockSEC:0001731122-24-000552:0
268,000 shares@ US$1.6040.7% of flowCommon StockSEC:0001731122-23-001246:0
50,000 shares@ US$0.92100.0% of flowCommon StockSEC:0001731122-22-001013:0
51,620 shares@ US$1.325.9% of flowCommon StockSEC:0001731122-21-001127:0
25,000 shares@ US$5.68100.0% of flowCommon StockSEC:0001731122-21-001126:0
37,500 shares@ US$1.20100.0% of flowCommon StockSEC:0001731122-21-000941:0
1,000 shares@ US$10.9348.3% of flowCommon StockSEC:0001731122-21-000916:0
Canonical exit: 15 Aug 2021 (T+90)
12 of 12 declarations
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (NASDAQ: AVXL) is a clinical-stage biopharmaceutical company headquartered in New York, NY, in the United States. For French-, Belgian-, and Swiss-based investors, the company fits the profile of a small-cap neuroscience biotech focused on oral, CNS-directed therapies rather than large-scale commercial products. Anavex says it is dedicated to developing innovative medicines for neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, with programs spanning Alzheimer’s disease, Parkinson’s disease, schizophrenia, Rett syndrome, Fragile X syndrome, infantile spasms, Angelman syndrome, and other central nervous system conditions. ([anavex.com](https://anavex.com/about/))
From a corporate-history perspective, Anavex has built its identity around a neuroscience platform aimed at restoring cellular homeostasis. Its lead and most closely watched asset is ANAVEX®2-73 (blarcamesine), an oral candidate positioned by the company as a key program in early Alzheimer’s disease and also explored across additional CNS indications. The pipeline also includes ANAVEX®3-71 for schizophrenia, alongside preclinical and earlier-stage programs in other neurological disorders. This gives the company a classic development-stage biotech profile: scientific upside can be substantial, but valuation remains highly sensitive to clinical data, regulatory feedback, and financing needs. ([anavex.com](https://anavex.com/news/anavex-life-sciences-receives-fda-feedback-on-alzheimers-disease-program/))
Read moreShow less
In competitive terms, Anavex operates in one of the most contested areas of biotech, where large pharmaceutical companies, well-funded smaller peers, and academic spinouts all pursue disease-modifying approaches in neurodegeneration. The company’s differentiator is its precision-therapy framing, including emphasis on SIGMAR1-related biology and genetic subgroups in parts of its Alzheimer’s dataset. For investors, that positioning can support meaningful rerating potential if the clinical and regulatory story continues to improve, but it also introduces meaningful binary risk if results fail to replicate or if regulators demand additional evidence. ([anavex.com](https://anavex.com/about/))
Recent developments in 2026 have been important for the equity story. Anavex reported regulatory and clinical updates around blarcamesine, including participation in the European ACCESS-AD initiative, new data presented at the AD/PD 2026 conference, and FDA feedback on its Alzheimer’s program. On May 6, 2026, the Board appointed Terrie Kellmeyer, PhD, as Interim Chief Executive Officer following Christopher Missling’s departure on April 30, 2026. For market participants, these events highlight a company that remains very catalyst-driven and highly sensitive to clinical and regulatory milestones. ([anavex.com](https://anavex.com/news/anavex-life-sciences-q1-2026-financial-results/?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
